| DOI: | https://doi.org/10.1021/acs.molpharmaceut.8b00087 |
|---|---|
| Reference: |
Pharmacological Characterization of the RPMI 2650 Model as a Relevant Tool for Assessing the Permeability of Intranasal Drugs |
| Disease Area: | Lung Cancer |
| Type: | RPMI2650 cell line - nasal mucosa |
| Application: | Drug development/ testing |
| Biological Endpoints: | Gene expression |
| Throughput: | Medium / Low (Lab scale) |
| Potential: | Drug Discovery |
| Authors: | Mercier, C. - Hodin, S. - He, ZG. - Perek, N. - Delavenne, X. |
| Year: | 2018 |
Did you find what you were looking for?
Yes, I found it! No, I did not!Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.
Please contact us by email if you have any questions.